Academic Literature

Association of Rebates in Part D with Patient OOP and Federal Spending

The way Medicare Part D's benefit design shows that rebates actually increase patients' out-of-pocket costs while shifting spending from plan sponsors and manufacturers to Medicare.
Originally published on 05/30/2017 in JAMA Internal Medicine

The increasing cost of prescription drugs is a burden for patients and threatens the financial stability of the US health care system.

Rebates are a form of price concession paid by a pharmaceutical manufacturer to the health plan sponsor or the pharmacy benefit manager working on the plan’s behalf. Proponents argue that rebates result from vigorous negotiations that help lower overall drug costs. Critics argue that rebates have perversely increased the costs patients pay out of pocket, as well as the costs for Medicare as a whole. This special communication discusses how the availability of rebates for drugs covered by the Medicare Part D program may raise costs for patients and Medicare while increasing the profits of Part D plan sponsors and pharmaceutical manufacturers. Two policy alternatives are herein proposed that would reconfigure cost sharing to lower patient out-of-pocket costs and reduce cost shifting to Medicare.

Find the full article here.


1) Aren’t there many types of rebates and discounts in the drug supply and payment chain? Is your paper relevant to all of them?

The terms “rebates” and “discounts” can in fact refer to a wide variety of different types of payments between different parties in the drug supply and payment chain. But we focus specifically on the rebates that manufacturers pay back to plans (and the PBM’s that work on behalf of the plans) in exchange for contract terms regarding those manufacturers products. We focus on these types of rebates because they cause a gap between the drug’s price at the pharmacy and the drug’s price for the plan. In our paper we refer to these two prices as the “list price” and the “net price” (the one after the rebate is subtracted from the list price).

2) What are the consequences of the gap between a drug’s list price and its net price on Medicare patients?

Under the standard benefit the patient pays a percentage of the drug’s price: 100% in the deductible, 25% in the initial coverage period, 50% in the coverage gap, 5% with no upper limit in catastrophic. When these percentages are based on a drug’s list price instead of the net price of the drug (which incorporates the rebate the manufacturer pays to the plan), these percentage based payments are larger. We show the impact comparing two Hepatitis C drug’s (Gilead’s Harvoni and Merck’s Zepatier), one that achieves a lower price than list through a rebate, the other than has a lower list price to begin with, and how patients in Medicare bear a much higher share of the price for the first one because of this. For a typical patient a course of treatment will cost around $2,000 more out of pocket for Gilead’s treatment.

In January 2017, CMS released a report in which it outlined the impact on beneficiaries of rising drug list prices on beneficiary payments.

3) What are the consequences of the gap between a drug’s list price and its net price on Medicare program spending?

Under the standard benefit and throughout the Medicare Part D program the structure of the benefit over the course of the year changes in relation to how much the Medicare patient has spent over that year. The general structure is that as the beneficiary spends money out of pocket for prescription drugs the plan picks up most of the cost early in the year, but Medicare through reinsurance picks up more of the cost later in the year. Because the amount the patient spends is related to a drug’s list price rather than its net price after rebates, higher list prices “push” the patient through the benefit earlier thus shifting costs more onto Medicare, and less onto the Part D plan.

This feature we describe was highlighted in reports from CMS as well as from Frier Levitt.

4) Does the shift from higher list prices towards Medicare reinsurance really increase costs to Medicare? Isn’t there a counterbalancing effect of lowering plan costs that lower the premiums Medicare pays?

Probably not. One common misperception of the system for paying for Part D is that it is zero-sum, meaning if you raise one type of costs (such as the amount Medicare pays in reinsurance), that lowers some other type of costs (such as the amount Medicare pays in plan premiums). But actually Part D is not set up that way, it is asymmetric. If a plan charges Medicare more for reinsurance than was projected, Medicare pays that amount to the plan dollar for dollar. But if the plan on the other hand ends up spending less than it projected, it does not return those savings dollar for dollar back to Medicare. The plan only pays back some, as dictated by the program’s risk corridor: the plan keeps 100% of the first 5% less it spends than projected, 50% of the next 5%, and 20% of everything beyond that. Here is an image of the risk corridor:

5) How does the shift towards Medicare reinsurance that is caused by higher list prices and larger rebates affect manufacturers? Does it matter to them?

Manufacturers of branded specialty drugs provide a 50% discount on those products for the portion that is dispensed in the coverage gap part of the benefit (also called the donut hole). In our paper we note that a drug having a higher list price exceeding a few thousand dollars will actually have less of a share of its fill dispensed in the coverage gap, meaning the manufacturer discounts less of that fill even after rebates.

Ours is the first report we know of that highlights this manufacturer benefit of having higher list prices and larger rebates achieving the same net price when drugs are several thousand dollars or more for a prescription.

6) You can see how this works in this interactive rebate calculator, which allows you to set up a list price and then enter a rebate amount that the manufacturer will pay the plan. It shows two different scenarios, one where the rebate is incorporated into the drug’s price for the Medicare beneficiary (what is called point of sale rebates), the other with the plan keeping the rebate and the patient paying the list price (how Part D in nearly all cases currently works). This calculator is a stylized illustration that assumes the plan bid was based on the list and net price of the drug being the same, so that the impact of a widening gap between the two can be seen, so the risk corridor reconciliation works off the net price baseline.

7) So mathematically having higher list prices and larger rebates shifts costs from Part D plans to Medicare reinsurance, but is there any evidence this is happening in any systematic way in Part D? Or is this just a theoretical exercise?

All of the trends in Part D are consistent with a recurring pattern in which increasing list prices and widening rebates are delivering extra profits to plans at the expense of Medicare patients and the Medicare program.

  • Reinsurance spending by Medicare is consistently exceeding plans’ projections of that spending in their bids (and is rising rapidly). Medicare faces 100% risk on this portion of Part D spending. Reinsurance is rapidly rising expense in Part D, accounting for 37% of Part D spending in 2015 (it was 16% of Part D spending in 2007) (Table IV.B10)
  • Plan spending is consistently falling below what the plans project they will spend, which means that they are earning profits above projected. Medicare does not receive 100% of excess profits, but instead only a share as dictated by risk corridors. Plans have returned excess profits every year since 2006 in the aggregate (Table IV.B10)
  • In March 2015 Medpac analysts prepared a slide showing these two trends together:
  • CMS showed the shift in liability in Part D in their January 2017 report away from plans and on to Medicare reinsurance.
  • Here are the raw data on each plan and how much it returned (or not) in excess profits compared to how much extra it collected in reinsurance (if any).

8) Is there evidence in Part D data that rebate levels are rising for specialty branded drugs in a manner that increase Plan and manufacturer profits at the expense of Medicare and Medicare patients?

Rebate levels in Part D are rising, as are net drug costs, although not as quickly, hence a widening rebate margin that drives the shift towards Medicare reinsurance.


This pattern of rising list prices and rebate percentages which has led to list prices rising faster than net prices has also been highlighted by industry analysts.

Neither academics nor CMS have the data that would be needed to answer this question directly. CMS has transaction level data from plans for each filled prescription, but the prices in those data are the same the patient pays. CMS has information on plan rebates, but that is aggregated to the level of the plan, not the individual drug and patient. The characteristics of these data are explained here on page 2.

9) What policy solutions do you propose?

In our paper we propose that the copayment structure of Part D be stabilized to reduce the shift towards Medicare reinsurance. One solution is called point-of-sale rebates, where the cost of a drug for the patient would be calculated based on the drug price inclusive of the rebate paid by the manufacturer to the Part D plan. CMS currently allows this structure but it is rarely used.

10) Doesn’t the law that created Part D require that plans incorporate rebates and discounts into a drug’s price for beneficiaries?

Not really. The Medicare Modernization Act of 2003 created Part D and requires that Part D plans must provide their enrollees access to negotiated prices. But negotiated price is a technical term, and it refers to the amount the plan agrees to pay the pharmacy (including dispensing fee) for dispensing a drug to an enrollee. The central tenet of our paper is that beneficiaries are paying more out of pocket than they should because these negotiated prices are higher than the prices net of rebates.

This is true even though the statute says that negotiated prices shall take into account negotiated price concessions, such as discounts, direct or indirect subsidies, rebates, and direct or indirect remunerations, for covered part D drugs, and include any dispensing fees for such drugs. CMS’s reading of the phrase “shall take into account” explains why Part D plans do not need to incorporate rebates into negotiated prices, although that reading does not prevent them from doing so.

In the initial promulgation of CMS’s Part D regulations in 2005 (through January 2016), CMS’s definition of negotiated price provided that negotiated prices “[a]re reduced by those discounts, direct or indirect subsidies, rebates, or other price concessions, and direct or indirect remuneration that the Part D sponsor has elected to pass through to Part D enrollees at the point of sale” (emphasis added). Responding to a comment that most or all price concessions should be passed through to beneficiaries, CMS explained in 2005 that, had Congress intended this result, it would have used a phrase other than “take into account.” CMS also explained that the statutory requirement that Part D plans disclose to CMS the manufacturer rebates that are passed through in the form of lower prices to enrollees presumes that some of these rebates may not be passed through. CMS concluded with “we interpret the [statutory] definition of the term negotiated prices [in the statute] as requiring Part D plans to pass on to enrollees some, but not necessarily all, of these price concessions.” CMS reiterated this interpretation in 2009, adding that rebates and certain price concessions are determined after the point of sale purchase, “making it difficult for Part D sponsors to always apply these amounts to the negotiated price at the point of sale.” At the time CMS predicted that “market competition will encourage Part D plans to pass though to enrollees a high percentage of the negotiated price concessions they obtain in the form of negotiated prices at the point of sale.”

In 2014, CMS stated that while “we expected these price concessions [included in negotiated prices] to be in the form of rebates offered by prescription drug manufacturers,” in fact virtually all concessions included in negotiated prices were provided by pharmacies. Accordingly, effective Jan.1, 2016, CMS amended the definition of negotiated prices so that it no longer requires reducing these prices by discounts that the Part D plan has elected to pass through to enrollees. Instead, negotiated prices must be reduced by price concessions from network pharmacies, unless they can’t be reasonably determined at the point of sale. In making this amendment, CMS insisted that, unless price concessions from pharmacies are included negotiated prices, the true cost of drugs is not transparent to the market and consumers cannot efficiently minimize their cost sharing and select the lowest cost drug/pharmacy combination. This “thwarts the very price competition that the Congress intended with respect to how private plans would compete with other plans on both premiums and negotiated prices.” This logic could be applied to manufacturer rebates, but CMS has not done so.


Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Limits on Medicare's Ability to Control Rising Spending on Cancer…
The growth in spending on cancer drugs can be attributed primarily to a unique legislative and regulatory framework that shields such drugs from the strategies that Medicare typically uses to hold down prices.
NEJM 02/05/2009
The Conflict Between QALYs and Well-Funded Patient Advocacy Groups
The goal of a QALY is to figure out how much any given drug is worth to a society so that we, as a society, have a benchmark to evaluate the price of pharmaceutical products.
Relentless Health Value 12/10/2020
Remdesivir Less Expensive for "Government Programs"? Not So Fast.
Two options are proposed if Gilead wishes to offer the discounts to the full array of government programs.
Drug Pricing Lab 07/01/2020
Blueprints for Indication-Specific Pricing
Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.
Drug Pricing Lab 05/19/2020
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Drop in Cancer Deaths Reflect Failures of Our Society. Really.
Despite declining cancer death rates, the nation still presents societal failures to improve the state of our population's health.
The Boston Globe 02/21/2020
Dissecting PhRMA's Opposition to H.R. 3 Lower Drug Costs Now…
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.
STAT News 10/11/2019
Time to Throw in the Towel on Biosimilars
Peter Bach and Mark Trusheim of MIT Sloan School of Management underscore the drawbacks of Washington's preferred solution to introduce competition for biologics, the biosimilar model.
The Wall Street Journal 08/21/2019
Mortgaging New Treatments Kicks the Can on High Drug Prices
The launch price for one-time gene therapy Zolgensma presents various implications.
Morning Consult 07/09/2019
A $475,000 price tag for a new cancer drug: crazy…
Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.
STAT News 08/31/2017
US Drug Prices And R&D, Take 2: A Reply To…
To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.
Health Affairs Blog 07/27/2017
Prevalence of Off-Label Use and Spending Among Patent-Protected Chemotherapies
The prevalence of off-label anticancer drug use is not well characterized.
JCO 02/19/2013

Featured News

See All News
Bloomberg Opinion 07/16/2020

Before Spending Billions, U.S. Hospitals Need to Study Remdesivir Further

As COVID-19 continually evolves and new therapies are approved and administered individually and in combination, the best way to apply scientific principle is to continue to test each treatment separately and together, beginning with Remdesivir.
Read Article

Stay up to date on our work and news